HSPA1A and breast carcinoma: The stronger killing effect of S1g-2 against tamoxifen-resistant breast cancer cell lines in cell-based experiments and in vivo differ it from all known Hsp70 inhibitors, endowing it as a first-in-class promising lead compounds.